INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41m ago
HOUSE PTR1m ago
SEC 13F55s ago
ROBINHOOD CHAIN48s ago
SEC FORM 4/Open-market saleVerified data

Chin Peter Scott sold DNLI

Chief Medical Officer · Denali Therapeutics Inc. · Common Stock

Side
SELL
Value
$37K
Shares
1,654
Price
$22.29
Executed
Sep 4, 2026
Disclosed
Sep 9, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Sep 4 executedSep 9, 2026 disclosed

DNLI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
32/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $37K reported value · 0.8% of prior position

Filing timing+6 / 15

Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DNLI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    10
    TN
    Thornberry NancyDirector
    DNLIDenali Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$15K
    615 sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    TN
    Thornberry NancyDirector
    DNLIDenali Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$247K
    10.8K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    8
    WJ
    Watts Ryan J.Director, President and CEO
    DNLIDenali Therapeutics Inc.
    Gift
    		G—
    32.2K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    20
    SO
    Schuth Alexander O.COFO and Secretary
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$72K
    2,857 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    36
    SO
    Schuth Alexander O.COFO and Secretary
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$284K
    17.2K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    36
    WJ
    Watts Ryan J.Director, President and CEO
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$581K
    35.2K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    DNLIDenali Therapeutics Inc.
    Grant or award
    		A—
    31.9K sh
    		Nov 4, 2025Nov 6, 2025
    traded Nov 4, 2025
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    DNLIDenali Therapeutics Inc.
    Grant or award
    		A—
    10.6K sh
    		Nov 4, 2025Nov 6, 2025
    traded Nov 4, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002124755-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 4, 2026
    Published
    Sep 9, 2026
    Ingested by INSIDER
    Nov 5, 02:18 UTC
    Last re-read
    Nov 5, 02:18 UTC

    Extracted facts

    Filer
    Chin Peter Scott
    Role
    Chief Medical Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Denali Therapeutics Inc.
    Ticker
    DNLI
    Shares
    1,654
    Price per share
    $22.29
    Value
    $36,868
    Execution date (reported)
    Sep 4, 2026
    Owned after transaction
    204.5K shares
    Days from execution to publication
    5

    Calculation

    Value = shares × reported price per share

    • Shares: 1,654
    • Price: $22.29

    = $36,868

    What this establishes

    Chin Peter Scott filed this Form 4 reporting a open-market sale of DNLI on Sep 4, 2026. It became public on Sep 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Chin Peter Scottcik:0002124755
    Issuer
    Denali Therapeutics Inc.cik:0001714899

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.